777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com
版塊:
行業:
全職員工: 13,926
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman | 8.18百萬 | 無 | 1953 |
Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 7.76百萬 | 無 | 1960 |
Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research | 1.68百萬 | 21.37百萬 | 1959 |
Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 2.01百萬 | 10.67百萬 | 1973 |
Mr. Christopher R. Fenimore CPA | Senior VP of Finance & CFO | 無 | 無 | 1971 |
Ms. Patrice Gilooly | Senior Vice President of Quality Assurance & Operations | 無 | 無 | 無 |
Mr. Bob McCowan | Senior VP of IT & Chief Information Officer | 無 | 無 | 無 |
Mr. Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis | 無 | 無 | 無 |
Mr. Joseph J. LaRosa | Executive VP, General Counsel & Secretary | 1.75百萬 | 23.23百萬 | 1959 |
Ms. Melissa Lozner | Senior VP & Chief Compliance Officer | 無 | 無 | 無 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
截至 2024年10月1日 止,Regeneron Pharmaceuticals, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中:9;董事會:10;股東權利:10;現金賠償:9。